Program Description & Educational Objectives
In this activity, an expert in ulcerative colitis discusses strategies to induce and maintain remission in two patient scenarios: A young man with a new diagnosis of mild-to-moderate ulcerative colitis, and a middle-aged woman experiencing a flare-up of ulcerative colitis. In addition, the activity will address long-term adherence and managing the risk of colorectal cancer.
Upon completion of this activity, participants should be better able to:
- Implement measures to improve patient compliance with first-line therapies in UC
- Review current evidence on chemoprotective qualities of 5-ASA
- Evaluate new data on efficacy, tolerability, and persistence of first-line treatment options used in UC, with focus on improved remission rates
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists and other clinicians involved in managing patients with ulcerative colitis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: August 12, 2010 - August 11, 2011
Time to Complete: 60 minutes
Faculty & Disclosure
Course Director and Interviewee
Seymour Katz, MD
Clinical Professor of Medicine
Albert Einstein College of Medicine
Yeshiva University
Bronx, New York
Seymour Katz, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott Laboratories; Procter & Gamble; and UCB Pharma, Inc.
Grant/Research Support from Abbott Laboratories; Bristol-Myers Squibb Company; Centocor Ortho Biotech; Cosmo Pharmaceuticals S.p.A.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Hutchison MediPharma Limited; Lexicon Pharmaceuticals, Inc.; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; Procter & Gamble; Prometheus Laboratories Inc.; Quest Diagnostics; Shire; and UCB Pharma, Inc.
Speakers Bureau participant with Procter & Gamble and UCB Pharma, Inc.
CME Reviewer
William D. Chey, MD, AGAF, FACG, FACP
Professor of Medicine
Director - GI Physiology Laboratory
Director - Michigan Bowel Control Program
Division of Gastroenterology
University of Michigan Medical School
Ann Arbor, Michigan
William D. Chey, MD, AGAF, FACG, FACP,
has a financial interest/relationship or affiliation in the form of:
Consultant for AGI Therapeutics plc, Allergan, Inc., Axcan Pharma Inc., Ironwood Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Procter & Gamble; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; and Takeda Pharmaceuticals North America, Inc.
Speakers Bureau participant with Axcan Pharma Inc., Procter & Gamble; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; and Takeda Pharmaceuticals North America, Inc.
Credit Designation
Mr. Pierre Lavalard, MBA
Associate Director
Office of CME
Department of Medical Education
University of Michigan Medical School
Ann Arbor, Michigan
Mr. Pierre Lavalard, MBA,
currently has no financial interests/relationships or affiliations in relation to this activity.
Content Director
Annette Wiggins
PVI, PeerView Institute for Medical Education, Inc.
Annette Wiggins
currently has no financial interests/relationships or affiliations in relation to this activity.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and PVI, PeerView Institute for Medical Education. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
The University of Michigan Medical School designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This educational activity is supported by an independent medical educational grant from 
